🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchOrforglipron ATTAIN-4 — cardiovascular outcomes arm Page 4

Orforglipron ATTAIN-4 — cardiovascular outcomes arm

TrialTracker_MD Mon, May 25, 2026 at 7:53 AM 21 replies 544 viewsPage 4 of 5
PeptideChemSF
Senior Member
1,890
9,012
Jan 2024
San Francisco, CA
May 28, 2026 at 1:10 PM#16
Dr.BariatricHTX said:
If two explanations both fit, the useful question is which one predicts something the other does not.

Same pattern here, and in the same order.

27 2steve_okc, dave_SLC, FDA_TrackerJim and 24 others
Reply Quote Save Share Report
LibrarianMeg
Senior Member
1,678
7,890
Mar 2024
Baltimore, MD
May 29, 2026 at 12:45 AM#17
PharmacoVig_BOS said:
Keep the original post as written when you update it, and add the correction underneath.

Saving this. It is the first explanation that did not require me to already understand it. Taking it to my next appointment.

26 1PharmD_Rodriguez, julia.endo, JessicaM_2024 and 23 others
Reply Quote Save Share Report
hans_munich
Member
534
2,345
Jul 2024
Munich, DE
May 29, 2026 at 12:20 PM#18

Adding the clinical framing, because it changes how the question reads. It helps to say which part of this you are uncertain about. A precise question gets a precise answer; a general one gets everybody’s favourite anecdote.

Last edited: May 29, 2026 at 6:20 PM
25 0Dr.LipidDallas, alex_tucson, kevin_tulsa and 22 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
paul_denver
Member
723
3,234
May 2024
Denver, CO
May 29, 2026 at 11:56 PM#19
hans_munich said:
It helps to say which part of this you are uncertain about.

This matches mine closely enough to be worth saying so out loud. Nothing to add that would improve it.

24 24sarah_TO, wendy_avl, jason_paloalto and 21 others
Reply Quote Save Share Report
Admin
Administrator
2,456
9,812
Oct 2023
Online
May 30, 2026 at 11:31 AM#20

Moderator note: the sourcing question belongs in the vendor section and has been split out. Report rather than reply if it drifts again.

2 2PeptideSynthNJ, Dr.KarenChen
Reply Quote Save Share Report

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register